The biotechnology sector of the stock market has one singularly unique aspect that differentiates it from any other sector - the FDA Advisory Committee Meeting, or Adcom, as it's commonly abbreviated. According to the FDA website, Adcoms are "committees and panels to obtain independent expert advice on scientific, technical and policy matters." But to companies that face them, they're perilous dates with destiny that almost always end in disappointment, conclusively determining the fate of a company's commercial product candidate and consequently, the size of a shareholder's remaining position in that company. Because of this, adcoms have become the very definition of the binary event which has one of only two possible outcomes - very positive or very negative.
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|